Sanofi is one of the world's leading pharmaceutical companies. Sanofi has been present in Colombia since 1996, promoting its products, medical representatives, research and development of new products, its industrial plant located in Cali and two distribution centers in Bogota, one for Sanofi and another For Sanofi Pasteur. Following the acquisition in March 2013 of Genfar S.A., the nationwide leader in generic medicines, Sanofi expanded its presence in the country with two industrial plants, one in Villarica, Cauca and one smaller dedicated to antibiotics in Bogota. Sanofi-Aventis was formed in 2004 when Sanofi-Synthelabo (created by the merger of Sanofi and Synthelabo in 1999) acquired Aventis (the result of the 1999 merger of Hoechst and Rhone-Poulenc).
Sanofi offers patients and health professionals in Colombia an efficient and effective therapeutic response to pathologies in 7 therapeutic areas: cardiotrombosis, oncology, diabetes, internal medicine, central nervous system, vaccines and generics.
Basic Information
Key Executives
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Deputy Member of the Board of Directors
Purchase this report to view the information.
Deputy Member of the Board of Directors
Ownership Details
Purchase this report to view the information.
Subsidiaries
Company Performance
Financial values in the chart are available after Sanofi-Aventis de Colombia S.A. report is purchased.
Looking for more than just a company report?
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency COP. Absolute financial data is included in the purchased report.
Net sales revenue
-18.15%▼
Total operating revenue
-13.21%▼
Operating profit (EBIT)
0.59%▲
Net Profit (Loss) for the Period
-23.83%▼
Operating Profit Margin (ROS)
1.51%▲
Net Profit Margin
-0.36%▼
Return on Equity (ROE)
-3.89%▼
Debt to Equity Ratio
0.37%▲